Br J Ophthalmol 2000;84:268-272
( March )
Treatment of conjunctival squamous cell carcinoma with topical
5-fluorouracil
Edoardo Midena, Claudia Degli Angeli, Massimo Valenti, Valentina de Belvis, Paolo Boccato
Ocular Oncology
Service, Institute of Ophthalmology, University of Padua, Padua, Italy
Correspondence to: Edoardo Midena, MD, Ocular Oncology Service, Institute of
Ophthalmology, University of Padova, Via Giustiniani 2, 35100 Padova,
Italy
Accepted for publication 22 September 1999
AIM
To evaluate the
efficacy of topical 5-fluorouracil (5-FU) alone, without concurrent
surgery or radiotherapy, for the treatment of conjunctival squamous
cell carcinoma.
METHODS
Eight
patients affected by conjunctival squamous cell carcinoma (three
recurrent cases, three incompletely excised, and two untreated cases)
were treated with 1% 5-FU eye drops. Topical 1% 5-FU was administered
four times daily for 4 weeks (one course). Clinical examination
(biomicroscopy and photography) and morphological evaluation of
conjunctival cytological specimens were used to monitor the efficacy of
local chemotherapy, side effects, and recurrences.
RESULTS
All patients
showed clinical regression of conjunctival carcinoma after topical 1%
5-FU treatment. Neoplastic conjunctiva was completely replaced by
normal epithelium within 3 months. Mean follow up was 27 months. One
patient needed two courses of local chemotherapy for recurrent disease.
An acute transient toxic keratoconjunctivitis was observed in all
treated cases; it was easily controlled with topical therapy. No long
term side effects were found.
CONCLUSIONS
Topical
1% 5-FU is effective in the treatment of recurrent, incompletely
excised, and selected untreated conjunctival squamous cell carcinomas.
Topical 1% 5-FU has no major complications. This study suggests that
topical conjunctival chemotherapy with 1% 5-FU may be useful, at least
as adjunctive therapy, in the treatment of conjunctival squamous cell carcinoma.
© 2000 by British Journal of Ophthalmology